GB1008583A - Controlled release medicaments - Google Patents
Controlled release medicamentsInfo
- Publication number
- GB1008583A GB1008583A GB1?823/62A GB182362A GB1008583A GB 1008583 A GB1008583 A GB 1008583A GB 182362 A GB182362 A GB 182362A GB 1008583 A GB1008583 A GB 1008583A
- Authority
- GB
- United Kingdom
- Prior art keywords
- mixture
- medicament
- enzyme
- vehicle
- controlled release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 title abstract 6
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 6
- 102000004190 Enzymes Human genes 0.000 abstract 5
- 108090000790 Enzymes Proteins 0.000 abstract 5
- 229940088598 enzyme Drugs 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 2
- 239000000758 substrate Substances 0.000 abstract 2
- 239000003826 tablet Substances 0.000 abstract 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 abstract 2
- 102000013142 Amylases Human genes 0.000 abstract 1
- 108010065511 Amylases Proteins 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 102000013382 Gelatinases Human genes 0.000 abstract 1
- 108010026132 Gelatinases Proteins 0.000 abstract 1
- 102000004882 Lipase Human genes 0.000 abstract 1
- 108090001060 Lipase Proteins 0.000 abstract 1
- 239000004367 Lipase Substances 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229940111205 diastase Drugs 0.000 abstract 1
- 230000001079 digestive effect Effects 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 235000019421 lipase Nutrition 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
A controlled release composition comprises a medicament and a pharmaceutically acceptable vehicle mixed with or dissolving the medicament, the vehicle being susceptible to the digestive action of an enzyme or mixture of enzymes, and the composition containing an enzyme or mixture of ensymes which is capable of digesting the vehicle. Two or more substrate/enzyme combinations may be employed in a dosage unit in order to obtain release of medicament over a period of time in a changing environment. Thus, a mixture of starch diastase, lipase and tristearin, with or without the further addition of gelatin and gelatinase, in the form of a tablet will allow an added drug such as a sulphonamide to be released in both the stomach and the intestine. The composition may take the form of an emulsion, suspension, tablet (oral, sublingual, buccal or vaginal), capsule, ointment or suppository. Lists of drugs, enzymes and substrates are included.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10529861A | 1961-04-25 | 1961-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1008583A true GB1008583A (en) | 1965-10-27 |
Family
ID=22305062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1?823/62A Expired GB1008583A (en) | 1961-04-25 | 1962-04-17 | Controlled release medicaments |
Country Status (3)
| Country | Link |
|---|---|
| BR (1) | BR6238314D0 (en) |
| FR (1) | FR2664M (en) |
| GB (1) | GB1008583A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989544A (en) * | 1989-05-16 | 1999-11-23 | Block Drug Company, Inc. | Composition and method for reducing gastro-intestinal distress due to alpha-D-galactoside-linked/containing sugars |
| US6598371B1 (en) | 1998-10-06 | 2003-07-29 | Stanelco Fibre Optics Ltd. | Capsules |
| DE102005049649A1 (en) * | 2005-10-18 | 2007-04-19 | Pro Natura Gesellschaft für gesunde Ernährung mbH | Composition, useful as e.g. nutritional supplement for the relief of gastro-intestinal tract complaints due to uptake of food containing oligosaccharide, comprises a combination of alpha-galactosidase and beta-fructofuraonosidase |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2051483A1 (en) * | 1969-05-19 | 1971-04-09 | Midy Centre Rech M | Proteolytic enzymes for treating throat - infections |
-
1962
- 1962-04-17 GB GB1?823/62A patent/GB1008583A/en not_active Expired
- 1962-04-23 BR BR138314/62A patent/BR6238314D0/en unknown
- 1962-04-25 FR FR895482A patent/FR2664M/en not_active Expired
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989544A (en) * | 1989-05-16 | 1999-11-23 | Block Drug Company, Inc. | Composition and method for reducing gastro-intestinal distress due to alpha-D-galactoside-linked/containing sugars |
| US6344196B1 (en) | 1989-05-16 | 2002-02-05 | Block Drug Company, Inc. | Compositions and method for reducing gastro-intestinal distress due to alpha-d-galactoside-linked/containing sugars |
| US6598371B1 (en) | 1998-10-06 | 2003-07-29 | Stanelco Fibre Optics Ltd. | Capsules |
| DE102005049649A1 (en) * | 2005-10-18 | 2007-04-19 | Pro Natura Gesellschaft für gesunde Ernährung mbH | Composition, useful as e.g. nutritional supplement for the relief of gastro-intestinal tract complaints due to uptake of food containing oligosaccharide, comprises a combination of alpha-galactosidase and beta-fructofuraonosidase |
Also Published As
| Publication number | Publication date |
|---|---|
| BR6238314D0 (en) | 1973-05-24 |
| FR2664M (en) | 1964-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1507521A (en) | Dosage unit | |
| US3574819A (en) | Pharmaceutical compositions for treating digestive disorders containing 4,7- phenanthrolin - 5,6 - quinone together with pancreatin,bromelin,dehydrocholic acid and 7 - iodo - 5 - chloro-8-hydroxyquinoline | |
| Gow et al. | Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fibrosis: Effectiveness of an enteric-coated preparation with and without antacids and cimetidine | |
| UA41995C2 (en) | PHARMACEUTICAL FORM OF AZITROMYCIN WITH CONTROLLED RELEASE (OPTIONS), METHOD OF ITS INTRODUCTION, METHOD OF ITS MANUFACTURE AND METHOD OF TREATMENT | |
| MY102459A (en) | Oral sustained release pharmaceutical preparation. | |
| HUP9701437A2 (en) | Use of complex lipides as stabilizing additives in pharmaceutical compositions containing digestive enzymes, pharmaceutical compns. and kits | |
| US3004893A (en) | Enteric coated trypsin and chymotrypsin anti-inflammatory compositions | |
| KR880007084A (en) | Pharmaceutical composition | |
| GB984464A (en) | Therapeutic compositions comprising bromelain | |
| GB1008583A (en) | Controlled release medicaments | |
| IE36611B1 (en) | Propanolamine derivatives their preparation and therapeutic compositions containing the same | |
| US2566200A (en) | Oral therapeutic tablets | |
| US2373763A (en) | Enteric coating | |
| ATE68435T1 (en) | PACKAGE FOR ADMINISTRATION OF A MEDICATION PREPARATION. | |
| Cohen et al. | The effect of colchicine on guinea pig intestinal enzyme activity | |
| FR2077913A1 (en) | Tablets contg gelatine capsules - for administration of liquid medicaments | |
| US3627875A (en) | Antipyretic and inflammation combatting compositions | |
| US3121044A (en) | Three-layer compressed penicillin tablet | |
| ES258952A1 (en) | Method for the production of an insulin preparation for peroral use | |
| GB1297221A (en) | ||
| GB955627A (en) | Therapeutic composition comprising antibiotics | |
| US4120975A (en) | Method of psychiatric conditions | |
| GB1056116A (en) | Enzyme-containing anti-asthmatic preparations | |
| GB861351A (en) | Antibiotic compositions and methods of preparing them | |
| GB1235540A (en) | Oral preparations containing proteolytic enzymes suitable for pediatric use |